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Background: Opiate substitution treatment has been associated with better adherence to lifesaving antiretroviral
medications, but the impact of other substance abuse treatment on adherence is unknown.
Findings: In this study, 215 patients who had been in adherence-focused research studies provided
electronically-measured adherence data and a measure of whether the patient had recently been in substance
abuse treatment. Recent engagement in substance abuse treatment was independently associated with
significantly higher adherence, after covarying for recent substance use and other factors potentially affecting
adherence.
Conclusions: The findings suggest that substance abuse treatment is associated with better adherence.
Potential mechanisms by which substance abuse treatment improves adherence, such as more stability or more
future-orientation, require further study.
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There are considerable data suggesting that current sub-
stance abuse is associated with both worse adherence to
antiretroviral medications and worse attendance at HIV
treatment visits [1]. HIV-positive patients who use drugs
or alcohol may be referred to standard substance abuse
treatment with the hope that medication adherence will
improve with abstinence.
However, among substance abuse treatments, only opi-
ate substitution treatment has consistently been asso-
ciated with better adherence, as summarized in a 2008
meta-analysis [2]. Both buprenorphine [3,4] and metha-
done maintenance [5,6] have been consistently associated
with better adherence. Patients who received both opiate
substitution treatment and directly observed therapy* Correspondence: Marc.Rosen@Yale.edu
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reproduction in any medium, provided the orhave shown even better adherence over time than with
those receiving opiate substitution alone [7,8].
It is not known whether enrollment in substance abuse
treatments other than opioid substitution is associated
with better adherence. In this study, we used data pooled
from two clinical trials of adherence-focused interven-
tions to test the hypotheses that HIV-infected people
who had recently been in substance abuse treatment
would have better antiretroviral adherence, and better
adherence over time, than those who had not had recent
substance abuse treatment.Methods
Overview and sampling
The data were drawn from two of the sixteen studies in
the MACH14 cohort [9]. The MACH 14 cohort is a
dataset pooled from 16 studies conducted at 14 sites
across 12 states. Each study in MACH14 used electronic
data monitoring (EDM) pillcaps to objectively measure
participants’ adherence to antiretroviral medication. Thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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abuse treatment so studies conducted in methadone
maintenance programs were not considered in this ana-
lysis. From the 1579 participants in the MACH14 data-
set, we identified 215 from two studies based outside
methadone clinics [10,11] because only these two stud-
ies’ participants had both EDM and substance abuse
treatment status data. Written informed consent was
obtained for participation in the parent studies, and the
Yale Institutional Review Board approved the secondary
analyses.
Patients were asked about engagement in substance
abuse treatment and use of specific substances for vary-
ing preceding timeframes: one of the two studies (n=47)
asked about participation in substance abuse treatment
during the past 90 days and use of specific substances
over the past 30 days, while the other study (n = 168)
asked about treatment over the past 30 days and sub-
stance use over past 14 days. To aggregate substance use
data across studies, variables representing use of specific
substances were defined as the proportion of days within
the asked-about timeframe the person had used each of
several substances.
This analysis used data collected at the first time-
point at which participants had EDM data for the pre-
ceding four weeks, had also been asked about being re-
cently enrolled in substance abuse treatment, and were
not enrolled in a methadone-clinic-based study. To es-
timate the effect of substance abuse treatment on ad-
herence, adherence was calculated for the four weeks
up to and including the date recent substance abuse
treatment enrollment was assessed, as well as for the
four weeks after the substance abuse treatment deter-
mination. Adherence in each week was calculated by
dividing the weekly number of doses taken by the
weekly number of prescribed doses for each medica-
tion, with adherence to each medication capped at
100%. Adherence for a patient on multiple anti-
retrovirals was calculated by averaging across pre-
scribed medications.
Data analysis
The effects of substance abuse treatment on adherence
were determined in multivariate analyses that included a
grouping variable denoting whether the patient was en-
rolled in substance abuse treatment and a variable
reflecting substance abuse treatment over time. The ana-
lyses were conducted controlling for sociodemographic
characteristics that might differ between patients in, and
not in, substance abuse treatment. To control for the
anticipated finding that patients in substance abuse
treatment would have more active drug use than a refer-
ence group including people who had never had signifi-
cant substance use, analyses included a measurerepresenting the largest proportion of days during which
participants had used either cocaine, opiates, or stimu-
lants. Cannabis use was not included in this measure of
illicit drug use because in a separate analysis of the
MACH14 dataset [12] and in an earlier study [13] recent
cannabis use was not associated with worse adherence.
Analyses were run with SAS 9.2. The model included
random effects for intercept and slope as this model had
better fit to the data than models with fixed effects only.
Results
Baseline characteristics
Overall, the sample was 65.7% male, and was composed
of 49.3% African American, 2.8% Hispanic, and 19.5%
Caucasian participants. Only 40.1% were employed.
Altogether, 39.5% were men who have sex with men
(MSM). Mean CD4+ count was 232.2 (+/− 206.9) and
8.5% of the 199 patients with viral load results available
had undetectable HIV viral loads (<400); these measures
of HIV disease did not differ between those in and those
not in substance abuse treatment. Mean adherence dur-
ing the first week was 82% (+/− 30%) overall, with 57.2%
(123/215) having 100% adherence, and 12.6% (27/215)
having adherence over 90% but less than 100%.
Of the 215 participants, 13 had recently been in sub-
stance abuse treatment— one had been in residential
treatment and the rest did not specify the type of treat-
ment attended. Table 1 compares those in substance
abuse treatment to those not in it; those in treatment
were less likely to be African American (Fisher’s Exact
Test =.04), and had used alcohol on a lower percentage
of days (t=5.9, p<.0001). Only one of the thirteen
patients in substance abuse treatment had used alcohol
recently and none had used other substances, whereas
there were substantial rates of recent use of several sub-
stances among those out of treatment.
Multivariate analysis
The multivariate analysis estimated the effects of socio-
demographic measures (age, gender, race/ethnicity,
MSM-status, employment), time in weeks, and max-
imum proportion days reported using an illicit drug
(Table 2). As expected, adherence was slightly and sig-
nificantly worse over time (estimate =−.02, p=.002).
Being in substance abuse treatment was associated with
better overall adherence (estimate =0.09, p= .05). The
week by treatment interaction was not statistically sig-
nificant and was removed from the model; substance
abuse treatment status did not significantly change ad-
herence over time.
Discussion
Substance use treatment may improve adherence by sev-
eral mechanisms. Although the analyses controlled for
Table 1 Baseline group characteristics
In Substance Abuse Treatment NOT In Substance Abuse Treatment Test Statistic df p
N mean +/− sd or % N mean +/− sd or %
Demographic Variables 13 202
Age 13 38.8+/−8.0 187 40.3+/−8.2 t=−0.63 198 NS
Gender (Male) 9 69.2% 131 65.5% = 0.08 1 NS
Ethnicity Fisher Exact 0.04
Caucasian 5 38.5% 37 18.3%
African American 2 15.4% 104 51.5%
Hispanic 0 0% 6 3.0%
Employed 2 18.2% 65 41.7% Fisher Exact NS
MSM 5 55.6% 80 63.5% Fisher Exact NS
HIV Markers
Mean CD4+ 13 295.4+/−202.6 186 227.8+/−207.0 t=1.14 197 NS
Non-Detectable (%) 12 92.3% 170 91.4% Fisher Exact NS
Substance Use Variables
Proportion Days Used Alcohol 13 0.0055+/−0.020 188 0.088+/−0.1775 t=−5.86 173.0 <.0001
% Recent Alcohol Use 1 7.7% 78 38.6% Fisher Exact 0.034
% Recent Cannabis 0 21 13.4%
% Recent Cocaine 0 7 3.5%
% Recent Heroin 0 2 0.99%
% Recent Stimulants 0 9 4.5%
% Used Any Illicit Drug 0 17 8.4%
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sures of substance use understated the impact of sub-
stance abuse treatment on substance abuse and that it is
in fact abstinence that facilitates adherence. In one of
the few randomized controlled studies of HIV-positive
drug users in which abstinence was the target outcome,
there was a trend towards a significant correlationTable 2 Impact of Predictors on Antiretroviral Adherence
[1]
Effect Estimate Pr >|t|
Intercept 0.82 <.0001
Week −0.02 0.0022
Recent Substance Abuse Treatment (yes/no) 0.09 0.0471
Male 0.08 0.0216
African American(Caucasian is Reference) 0.05 NS
Hispanic 0.07 NS
Other Race 0.05 NS
Illicit Drug Use (largest proportion of days
reported use of illicit drug other than cannabis)
−0.13 NS
Man who has Sex with Men 0.02 NS
Employed −0.03 NS
1-Adherence was proportion of prescribed doses taken during an eight week
period comprising each of 4 weeks before and 4 weeks after substance abuse
treatment status was inquired about.between consecutive weeks of toxicology-tested abstin-
ence during the intervention and reductions in viral load
[14]. There is also evidence from a naturalistic longitu-
dinal cohort study that attendance at HIV treatment, a
sine qua non for adherence, appears to improve with
newly-achieved abstinence [1].
Substance abuse treatment might improve adherence
by mechanisms other than facilitating abstinence from
using drugs. Substance abuse treatment typically
involves case management [15] to address the unstable
housing characteristic of drug users [16]. Stable housing
arrangements during substance abuse treatment would
be expected to foster adherence, in that stable routines
have been associated with better adherence [17]. Sub-
stance abuse treatment also focuses patients on future
goals, an orientation that has been described as fostering
adherence [18], and substance abuse treatment can in-
volve re-arranging social networks in ways that also
might foster better adherence [19].
It is possible that enrollment in substance abuse treat-
ment reflects a lurking un-measured variable associated
with both being in substance abuse treatment and better
adherence. The finding of better adherence among
people in substance abuse treatment was not buttressed
by finding better adherence over time among patients in
treatment. However, it might have been difficult to
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treatment because the data did not specify when patients
were entering, continuing, or finishing substance abuse
treatment.
There are several other caveats in interpreting these
findings. Substance abuse was measured by self-report,
and it is possible that substance abuse was dispropor-
tionately under-reported by people out of substance
abuse treatment, thus exaggerating the impact of sub-
stance abuse treatment on adherence. The type of sub-
stance abuse treatment was not specified and the
findings may not apply to all types of substance abuse
treatment. Finally, the sample size was modest, and the
number of participants in substance abuse treatment
was small. It is noteworthy that although adherence
decreased on average over time, the course of adherence
varied significantly by person. Further analyses should
test variables that may account for individual differences
in adherence over time.
These findings lend some support to the clinical prac-
tice of addressing substance use in an effort to improve
adherence. The crucial next step is to develop and pro-
spectively test substance abuse-focused interventions for
patients with both substance abuse and adherence
problems.
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